Kelvin Davies

Has grant

Professor

Albert Einstein College of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Kelvin Davies is a Professor at the Albert Einstein College of Medicine in the United States. His research focuses on erectile dysfunction, specifically related to cavernous nerve injury and its implications following pelvic surgery. He has contributed to understanding the synergistic effects of nitric oxide and PDE5 inhibitors, as well as the role of Opiorphin genes in prostate cancer growth. His recent work also explores the impacts of hyperglycemia on bladder detrusor function.

Recent Grants

Grant: Close

The microtubule cytoskeleton as a novel target for cavernous nerve regeneration after prostatectomy

Open Date: 2017-04-01

Close Date: 2021-03-31

Grant: Close

Evidence for a Distinct Gut Microbiome in Kidney Stone Formers

Open Date: 2016-08-18

Close Date: 2018-07-31

Grant: Close

Opiorphin as a master regulator of pathways leading to priapism

Open Date: 2016-01-15

Close Date: 2020-11-30

Grant: Close

Involvement of opiorphins and polyamine synthesis in the development of priapism

Open Date: 2011-09-15

Close Date: 2015-07-31

Grant: Close

Opiorphin as a master regulator of pathways leading to priapism

Open Date: 2009-09-15

Close Date: 2016-08-31

Articles (6)

Year:

2026

This study aimed to evaluate the effectiveness of combining a nitric oxide microparticle delivery system (NO-MP) with various FDA-approved PDE5 inhibitors (PDE5i) for improving erectile responses in a rat model of erectile dysfunction (ED) following cavernous nerve injury, similar to the effects of radical prostatectomy. Male Sprague-Dawley rats, 4–5 months old (weighing ~275 g) underwent bilateral cavernous nerve transection. One week post-surgery animals were administered PDE5i via oral gavage (sildenafil 0.05 mg/kg ( N = 9), tadalafil 0.005 mg/kg ( N = 8), vardenafil 0.01 mg/kg ( N = 7), avanafil 0.1 mg/kg ( N = 8) or untreated ( N = 5) followed by topical application of 250 mg NO-MP to the penile dermis. Erectile responses were assessed by measuring intracorporeal pressure (ICP) and systemic blood pressure (BP) after the application of NO-MP. Compared to NO-MP alone, combination therapy with a PDE5i significantly ( P < 0.05) reduced the time to initial erectile response from 63 ± 21.6 min to 8–23 min (vardenafil: 23 ± 2.3, avanafil: 11 ± 8.1, sildenafil: 19.9 ± 9.8, tadalafil: 18 ± 12.8), and increased the frequency of spontaneous erections from 1 ± 0.71 to 1.7–2.7 per hour (vardenafil: 2.1 ± 0.9, avanafil: 2.7 ± 1.1, sildenafil: 1.7 ± 0.6, tadalafil: 2.5 ± 0.8). No significant changes in maximal ICP/BP, duration of erectile response or baseline ICP/BP were observed. These results suggest that combining NO-MP with PDE5i may provide a promising approach for treating ED after radical prostatectomy.

Year:

2025

Year:

2022

Year:

2022

Year:

2021

Year:

2020